These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
610 related articles for article (PubMed ID: 24991840)
1. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840 [TBL] [Abstract][Full Text] [Related]
2. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839 [TBL] [Abstract][Full Text] [Related]
3. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983 [TBL] [Abstract][Full Text] [Related]
4. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838 [TBL] [Abstract][Full Text] [Related]
5. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Sarkaria JN; Galanis E; Wu W; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Buckner JC Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):468-75. PubMed ID: 20864273 [TBL] [Abstract][Full Text] [Related]
6. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835 [TBL] [Abstract][Full Text] [Related]
7. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Chinnaiyan P; Won M; Wen PY; Rojiani AM; Wendland M; Dipetrillo TA; Corn BW; Mehta MP Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):880-4. PubMed ID: 23725999 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509 [TBL] [Abstract][Full Text] [Related]
9. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. Sher DJ; Henson JW; Avutu B; Hochberg FH; Batchelor TT; Martuza RL; Barker FG; Loeffler JS; Chakravarti A J Neurooncol; 2008 May; 88(1):43-50. PubMed ID: 18231723 [TBL] [Abstract][Full Text] [Related]
10. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159 [TBL] [Abstract][Full Text] [Related]
12. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866 [TBL] [Abstract][Full Text] [Related]
13. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution. Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649 [TBL] [Abstract][Full Text] [Related]
14. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857 [TBL] [Abstract][Full Text] [Related]
15. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Butowski N; Chang SM; Lamborn KR; Polley MY; Parvataneni R; Hristova-Kazmierski M; Musib L; Nicol SJ; Thornton DE; Prados MD Neuro Oncol; 2010 Jun; 12(6):608-13. PubMed ID: 20156802 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282 [TBL] [Abstract][Full Text] [Related]
17. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662 [TBL] [Abstract][Full Text] [Related]
18. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]